Sonakshi Sinha expresses pride as her film Nikita Roy releases alongside Kajol's Maa. She welcomes the box office clash as a positive moment for both actresses.

I am initiating a 'sell' rating on Hims & Hers Health, with a fair value of $35 per share, due to imminent growth risks.

It’s not often that investors come across the kind of companies that can yield a multi-bagger investment over the years.

Novo Nordisk ends Wegovy deal with Hims over legal issues, sending the stock tumbling. What happens next? Here's a look.

Gwyneth Paltrow broke out white shorts for summer. While we think they’re a $650 pair from Max Mara, there’s an Amazon alternative that may also catch your eye. Shoppers praise the “flattering” ...

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...

Hims & Hers delivered record Q1 results and expanded into Europe with the Zava acquisition. Click here to see why HIMS stock is a Hold.

The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...